Article

Probiotic bacteria and intestinal epithelial barrier function

Department of Physiology and Pharmacology, Univ. of Calgary, 3330 Hospital Dr. NW, Calgary, AB, Canada T2N 4N1.
AJP Gastrointestinal and Liver Physiology (Impact Factor: 3.74). 03/2010; 298(6):G807-19. DOI: 10.1152/ajpgi.00243.2009
Source: PubMed

ABSTRACT The intestinal tract is a diverse microenvironment where more than 500 species of bacteria thrive. A single layer of epithelium is all that separates these commensal microorganisms and pathogens from the underlying immune cells, and thus epithelial barrier function is a key component in the arsenal of defense mechanisms required to prevent infection and inflammation. The epithelial barrier consists of a dense mucous layer containing secretory IgA and antimicrobial peptides as well as dynamic junctional complexes that regulate permeability between cells. Probiotics are live microorganisms that confer benefit to the host and that have been suggested to ameliorate or prevent diseases including antibiotic-associated diarrhea, irritable bowel syndrome, and inflammatory bowel disease. Probiotics likely function through enhancement of barrier function, immunomodulation, and competitive adherence to the mucus and epithelium. This review summarizes the evidence about effects of the many available probiotics with an emphasis on intestinal barrier function and the mechanisms affected by probiotics.

1 Follower
 · 
446 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Exposure to antibiotics is the major risk factor for Clostridium difficile diarrhea (CDD), suggesting that impairment of colonization resistance due to depletion of the gut flora is a significant underlying disease susceptibility factor. Many properties of probiotic organisms indicate that they may be able to replenish the depleted gut flora and restore colonization resistance. However, despite numerous clinical trials, the evidence base for probiotics in the prevention of CDD remains weak. A recent large trial of a multistrain, high-dose probiotic did not show clear evidence of efficacy. The role of probiotics in the prevention of CDD remains unclear. Copyright © 2015 Elsevier Inc. All rights reserved.
    Infectious Disease Clinics of North America 03/2015; 29(1):135-144. DOI:10.1016/j.idc.2014.11.002 · 2.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Probiotics are live microorganisms that, when ingested in adequate amounts, provide health benefits to the host. The strains most frequently used as probiotics include lactic acid bacteria and bifidobacteria, which are isolated from traditional fermented products and the gut, faeces and breast milk of human subjects. The identification of microorganisms is the first step in the selection of potential probiotics. The present techniques, including genetic fingerprinting, gene sequencing, oligonucleotide probes and specific primer selection, discriminate closely related bacteria with varying degrees of success. Additional molecular methods, such as denaturing gradient gel electrophoresis/temperature gradient gel electrophoresis and fluorescence in situ hybridisation, are employed to identify and characterise probiotics. The ability to examine fully sequenced genomes has accelerated the application of genetic approaches to elucidate the functional roles of probiotics. One of the best-demonstrated clinical benefits of probiotics is the prevention and treatment of acute and antibioticassociated diarrhoea; however, there is mounting evidence for a potential role for probiotics in the treatment of allergies and intestinal, liver and metabolic diseases. These positive effects are generally attributed to the ability of probiotics to regulate intestinal permeability, normalise host intestinal microbiota, improve gut immune barrier function and equilibrate the balance between pro-inflammatory and antiinflammatory cytokines. However, the positive effects of probiotics are not always substantiated by findings from properly conducted clinical trials. Notably, even when the results from randomised, placebo-controlled trials support the beneficial effects of a particular probiotic for a specific indication, the benefits are generally not translatable to other probiotic formulations
    The British journal of nutrition 01/2013; 109:S35-50. DOI:10.1017/S0007114512004011 · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The concentration of secretory IgA (sIgA) in intestine flush and solid organs (spleen, bursa) in chickens pretreated with probiotic strain Enterococcus faecium AL41 (EF) and challenged with Salmonella Enteritidis PT4 (SE) was assessed. Forty 1-day-old chickens Cobb 500 were divided into four groups: control, EFAL41, SE and combined EFAL41+SE. The increased concentration of sIgA was determined on day 4 after salmonella infection in the intestine flush in EFAL41group. In combined EFAL41+SE group significant increase of sIgA in the intestine flush was found 7 days post-infection. Pre-treatment of chickens with E. faecium AL41 also showed beneficial effect in bursa in EFAL41 and EFAL41+SE groups. In spleen, total IgA was increased only in SE group. The results demonstrated positive effect of E. faecium AL41 on IgA production in chickens' intestine and solid organs after S. Enteritidis PT4 challenge. Validity of method using for IgA evaluation in solid organ was proved.
    Food and Agricultural Immunology 12/2014; 26(3):1-5. DOI:10.1080/09540105.2014.918587 · 0.98 Impact Factor

Full-text (2 Sources)

Download
36 Downloads
Available from
Jun 11, 2014